Patents Examined by Sarah Pihonak
  • 3-(5-chloro-2-oxobenzo[d]oxazol-3(2H)-yl) propanoic acid derivatives as KMO inhibitors
    Patent number: 11352334
    Abstract: A compound of formula (I) or a salt thereof are provided: wherein R1, X and R3 are defined in the specification, useful in the treatment of disorders mediated by KMO such as acute pancreatitis, chronic kidney disease, other conditions associated with systemic inflammatory response syndrome (SIRS), Huntington's disease, Alzheimer's disease, spinocerebellar ataxias, Parkinson's disease, AIDS-dementia complex, amylotrophic lateral sclerosis (ALS), depression, schizophrenia, sepsis, cardiovascular shock, severe trauma, acute lung injury, acute respiratory distress syndrome, acute cholecystitis, severe burns, pneumonia, extensive surgical procedures, ischemic bowel, severe acute hepatic disease, severe acute hepatic encephalopathy or acute renal failure.
    Type: Grant
    Filed: July 24, 2019
    Date of Patent: June 7, 2022
    Assignee: THE UNIVERSITY COURT OF THE UNIVERSITY OF EDINBURGH
    Inventors: Anne Marie Jeanne Bouillot, Olivier Mirguet, John Liddle, Anne Louise Walker
  • Pharmaceutical composition and use for applying ribociclib in phosphodiesterase 4-mediated disease treatment of patient and inhibition of phosphodiesterase 4 activity
    Patent number: 11351172
    Abstract: The invention provides a pharmaceutical composition for treating phosphodiesterase 4-mediated (PDE4-mediated) disease in a patient and inhibition of phosphodiesterase 4 (PDE4) activity. The pharmaceutical composition includes an effective amount of Ribociclib and a pharmaceutically acceptable carrier. The invention further provides a use of the pharmaceutical composition for treating PDE4-mediated disease in a patient. The application of the pharmaceutical composition of the present invention and use thereof are advantageous for inhibiting of PDE4 activity and thus treating a PDE4-mediated disease.
    Type: Grant
    Filed: February 18, 2020
    Date of Patent: June 7, 2022
    Assignee: CHANG GUNG UNIVERSITY
    Inventors: Tsong-Long Hwang, Po-Jen Chen
  • Anticonvulsant compounds
    Patent number: 11345652
    Abstract: The present application relates to compounds and methods for reducing the severity of convulsant activity or epileptic seizures, or for the treatment of chronic or acute pain.
    Type: Grant
    Filed: December 20, 2019
    Date of Patent: May 31, 2022
    Assignee: OWEN-BARRY PHARMACEUTICALS
    Inventors: Michael Poulter, Tony Durst
  • Composition for use in treating rotavirus infection
    Patent number: 11344523
    Abstract: The present invention relates to a composition comprising at least one carboxylic acid selected from butanoic acid, hexanoic acid, octanoic acid, decanoic acid, and dodecanoic acid for use in treating a viral infection. Also disclosed is use of a composition comprising at least one carboxylic acid selected from butanoic acid, hexanoic acid, octanoic acid, decanoic acid, and dodecanoic acid in the manufacture of a medicament for treating a viral infection; and a method for treating a viral infection in a subject.
    Type: Grant
    Filed: March 23, 2020
    Date of Patent: May 31, 2022
    Assignee: Devenish Nutrition Limited
    Inventors: Violet Emma Beattie, Gordon Moore Allan, Andrena Millar, John Paul McKillen
  • Substituted pyrazolopyrimidines useful as kinases inhibitors
    Patent number: 11344553
    Abstract: The present disclosure is directed to novel pyrzaolopyrimidines, their derivatives, pharmaceutically acceptable salts, solvates and hydrates thereof. The compounds and compositions of the present disclosure have protein kinases inhibitory activities and are expected to be useful for the treatment of protein kinases mediated diseases and conditions.
    Type: Grant
    Filed: August 9, 2018
    Date of Patent: May 31, 2022
    Assignee: Teligene Ltd.
    Inventor: Dawei Zhang
  • Formulations comprising triptan compounds
    Patent number: 11337962
    Abstract: The invention provides a pharmaceutical composition for intranasal administration comprising a salt of sumatriptan or a physiologically acceptable solvate thereof, an alkyl glycoside or saccharide alkyl ester and optionally at least one pharmaceutically acceptable excipient, wherein the said composition provides Tmax value of less than 30 minutes upon said administration. Other aspects and embodiments are contemplated and described. The invention also provides a pharmaceutical composition for intranasal administration comprising a triptan, a pharmaceutically acceptable vehicle and a mucosal permeation enhancer, wherein upon said administration said composition provides a Tmax substantially equivalent to subcutaneous administration of said triptan. Other aspects and embodiments are contemplated and described.
    Type: Grant
    Filed: February 20, 2020
    Date of Patent: May 24, 2022
    Assignee: Upsher-Smith Laboratories, LLC
    Inventors: Rajesh Gandhi, Sreekanth Manikonda, Arun Jana, Sameer Shrinivas Kunte
  • Pharmaceutical combinations comprising a histone deacetylase inhibitor and a CD38 inhibitor and methods of use thereof
    Patent number: 11337975
    Abstract: The present disclosure relates to a pharmaceutical combination comprising (a) a histone deacetylase inhibitor and (b) a CD38 inhibitor, including combined preparations and pharmaceutical compositions thereof; uses of such combination in the treatment or prevention of cancer; and methods of treating or preventing cancer in a subject comprising administering a therapeutically effective amount of such combination.
    Type: Grant
    Filed: November 22, 2017
    Date of Patent: May 24, 2022
    Assignee: Acetylon Pharmaceuticals, Inc.
    Inventors: Steven Norman Quayle, Simon Stewart Jones, Teru Hideshima, Kenneth C. Anderson
  • Liquid oral formulations for sildenafil
    Patent number: 11337979
    Abstract: The present disclosure is directed to pharmaceutical compositions comprising a PDE V inhibitor and one or more pharmaceutical excipients or additives wherein the pharmaceutical compositions are in the form of liquid pharmaceutical compositions. The pharmaceutical compositions of the present disclosure are useful for the treatment of diseases or conditions which are treatable by administration of PDE V inhibitor drug such as pulmonary arterial hypertension, erectile dysfunction, etc.
    Type: Grant
    Filed: August 16, 2021
    Date of Patent: May 24, 2022
    Assignee: LIQMEDS WORLDWIDE LIMITED
    Inventors: Jinal Pandya, Sandip P. Mehta, Manish Umrethia, Jayanta Kumar Mandal, Hiren Pansuriya
  • Penicillin-binding protein inhibitors
    Patent number: 11332485
    Abstract: Described herein are certain boron-containing compounds, compositions, preparations and their use as modulators of the transpeptidase function of bacterial penicillin-binding proteins and as antibacterial agents. In some embodiments, the compounds described herein inhibit penicillin-binding proteins. In certain embodiments, the compounds described herein are useful in the treatment of bacterial infections.
    Type: Grant
    Filed: May 25, 2018
    Date of Patent: May 17, 2022
    Assignee: VENATORX PHARMACEUTICALS, INC.
    Inventors: Christopher J. Burns, Denis Daigle, Guo-Hua Chu, Jodie Hamrick, Matthew Lucas, Steven A. Boyd, Allison L. Zulli, Eugen F. Mesaros, Stephen M. Condon, Robert E. Lee Trout, Cullen L. Myers
  • Dosing regimens for the treatment of fungal infections
    Patent number: 11324728
    Abstract: Described herein are dosing regimens for the treatment of fungal infections such as onychomycosis using ravuconazole or a salt, solvate or prodrug thereof.
    Type: Grant
    Filed: November 28, 2018
    Date of Patent: May 10, 2022
    Assignee: Seren Pharmaceuticals Inc.
    Inventors: Osamu Ogawa, Hideyo Yamaguchi
  • Cleaning composition
    Patent number: 11326131
    Abstract: A cleaning and disinfecting composition comprises a long-chain alkyl polyamine, such as dodecyl dipropylene triamine; a long-chain quaternary ammonium salt, such as N,N-didecyl-N,N-dimethylammonium chloride; and a metal carbonate salt, such as potassium carbonate, all in aqueous solution. A sequestering agent, a long-chain alkyl polyethoxylate, an alkanolamine and an anti-corrosive agent may also be present. The composition has a pH of at least 11 when diluted to an in-use concentration, and may be used to clean and disinfect hard surfaces, such as medical, dental and surgical implements, walls, floors, sinks and hard furnishing surfaces, or soft surfaces such as bedding, upholstery or clothing. The composition is effective as a virucide, a sporicide, a bacteriocide, a fungicide, and against yeasts and moulds, without harming the substrate cleansed.
    Type: Grant
    Filed: October 4, 2018
    Date of Patent: May 10, 2022
    Assignee: AMITY LIMITED
    Inventors: Mokhles Tangestani-Nejad, Ram Singh
  • Methods for treating testicular and ovarian adrenal rest tumors
    Patent number: 11304950
    Abstract: Provided herein are compounds and pharmaceutical compositions for the prevention and treatment of testicular adrenal rest tumors (TART) or ovarian adrenal rest tumors (OART).
    Type: Grant
    Filed: October 27, 2020
    Date of Patent: April 19, 2022
    Assignee: SPRUCE BIOSCIENCES, INC.
    Inventors: Alexis Howerton, Hal Gerber
  • Use of I-BRD9 or derivatives thereof in preparing anti-epileptic drugs
    Patent number: 11304935
    Abstract: Provided are methods of using bromodomain-containing protein 9 inhibitor (I-BRD9) or a derivative thereof in preparation of anti-epileptic drugs. The I-BRD9 has significant effects on anticonvulsion, prolonging of convulsion latency, and reduction of seizure level, and can be used for preparing anti-epileptic drug preparations.
    Type: Grant
    Filed: September 25, 2019
    Date of Patent: April 19, 2022
    Assignee: UNIVERSITY OF SOUTH CHINA
    Inventors: Wenyu Cao, Yang Xu, Dan Luo, Wei Wan, Jie He, Xiaolin Zhong, Xi Chen, Zhenghai Liu, Jiayu Zeng, Zhen Wang, Hui Yang, Lei Niu, Shishi Luo
  • Heterocyclic compounds and uses thereof
    Patent number: 11299493
    Abstract: Heterocyclic compounds as Wee1 inhibitors are provided. The compounds may find use as therapeutic agents for the treatment of diseases and may find particular use in oncology.
    Type: Grant
    Filed: October 9, 2018
    Date of Patent: April 12, 2022
    Assignee: Nuvation Bio Inc.
    Inventors: Sarvajit Chakravarty, Son Minh Pham, Jayakanth Kankanala, Anil Kumar Agarwal, Brahmam Pujala, Sanjeev Soni, Satish K. Arya, Deepak Palve, Ashu Gupta, Varun Kumar
  • Anti-inflammatory composition
    Patent number: 11298353
    Abstract: The present invention relates to an anti-inflammatory composition, and more particularly to an anti-inflammatory composition containing, as an active ingredient, a compound represented by Formula 1 or a salt thereof, wherein the anti-inflammatory composition may inhibit inflammatory response even at an early stage by inhibiting the interaction between CD14 and LPS and blocking the expression of CD14 and the expression of TNF? and IL-1?, which are the key factors in inflammatory response, and may also regulate the expression of important factors, such as CCL2 (MCP-1), CCL7 (MCP-3), CXCL2, CHOP and NOX1, which are involved in inflammatory response.
    Type: Grant
    Filed: December 18, 2019
    Date of Patent: April 12, 2022
    Assignee: OSTEONEUROGEN INC.
    Inventors: Byung Soo Youn, Han Soo Kim, Ik Hwan Kim, Ho Sup Yoon, Moon Kee Maeng, Baik Lin Seong, Min Ju Ham, Hyeong Deok Choi
  • Prevention and treatment of diabetic nephropathy
    Patent number: 11291641
    Abstract: Embodiments herein disclose methods relating to diabetic nephropathy (DN); methods for preventing the onset and also for preventing the progressing of DN, as well as the treatment of DN in diabetic subjects comprising administering reparixin and/or ladarixin which are inhibitors of CXCL8 receptor CXCR1 and CXCR2 activation.
    Type: Grant
    Filed: October 3, 2017
    Date of Patent: April 5, 2022
    Assignees: THE CHILDREN'S MEDICAL CENTER CORPORATION, DOMPE FARMACEUTICI S.P.A.
    Inventors: Paolo Fiorina, Roberto Bassi, Andrea Vergani, Marcello Allegretti
  • Treatment of CNS conditions
    Patent number: 11285139
    Abstract: Aspects of the present invention relate to a method of treating an epileptic encephalopathy in a mammal in need thereof, comprising administering a composition comprising an effective amount of (4-benzyl-4-hydroxypiperidin-1-yl) (2,4?-bipyridin-3-yl)methanone or a pharmaceutically acceptable salt thereof to the mammal.
    Type: Grant
    Filed: August 30, 2018
    Date of Patent: March 29, 2022
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Toshiya Nishi, Shinichi Kondo
  • Pharmaceutical combinations for treating cancer
    Patent number: 11285155
    Abstract: The present invention relates to pharmaceutical combinations comprising a PPAR agonist and a P38 inhibitor for use in a method for the prevention, delay of progression or treatment of cancer.
    Type: Grant
    Filed: June 6, 2017
    Date of Patent: March 29, 2022
    Assignee: SUPPORT-VENTURE GMBH
    Inventor: Alexander Bausch
  • Topical phenytoin for use in the treatment of peripheral neuropathic pain
    Patent number: 11285099
    Abstract: The present disclosure relates to pharmaceutical compositions containing phenytoin or phenytoin sodium for use in topical pain relief. Use of the pharmaceutical composition of the disclosure reduces peripheral neuropathic pain. The topical pharmaceutical compositions of the disclosure containing phenytoin or phenytoin sodium, surprisingly reduce peripheral neuropathic pain considerably, especially and preferably in the conditions, characterized by a low to moderate grade of peripheral neurogenic inflammation, such as small fiber neuropathy, diabetic neuropathy, chronic idiopathic axonal polyneuropathy, post-herpetic neuralgia, trigeminus neuralgia, chemotherapy induced polyneuropathy, traumatic neuropathies, compression neuropathies, and infectious neuropathies in remission, according to the disclosure.
    Type: Grant
    Filed: December 6, 2017
    Date of Patent: March 29, 2022
    Assignees: Topical Innovations B.V.
    Inventors: David Jos Kopsky, Jan Marius Keppel Hesselink
  • Calcium lactate compositions and methods of use
    Patent number: 11285121
    Abstract: The invention relates to pharmaceutical compositions comprising calcium lactate as an active agent and a polysaccharide, polymer, lipid, or a combination thereof. The pharmaceutical compositions are useful treating cancer. The invention also relates to foods and nutrient compositions comprising calcium lactate.
    Type: Grant
    Filed: July 7, 2017
    Date of Patent: March 29, 2022
    Assignee: MetiMedi Pharmaceuticals Co., Ltd.
    Inventors: Chong Hwan Chang, Keun-Yeong Jeong